J07BK02 - Zoster, Live Attenuated |
Propably not porphyrinogenic |
PNP |
Rationale
Based on its pharmacokinetics properties the zoster vaccine has no conceivable porphyrinogenic effects.
Chemical description
Varicella-zoster virus live, attenuated. Produced in human diploid cells
Therapeutic characteristics
The zoster-vaccine is indicated for prevention of herpes zoster and herpes zoster-related post-herpetic neuralgia (PHN), in individuals over 50 years.
The vaccine can be injected subcutaneously or intramuscularly as a single dose.
Metabolism and pharmacokinetics
The zoster vaccine is not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Zostavax. (Last edition:
February. 2016). |
|
Tradenames
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax vaccine 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Zostavax 
Vaccines